Cargando…

Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer

Detalles Bibliográficos
Autores principales:	Wang, Dong, Du, Ruikai, Liu, Suling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372300/ https://www.ncbi.nlm.nih.gov/pubmed/28359295 http://dx.doi.org/10.1186/s40880-017-0204-9

Ejemplares similares

Rad51 supports triple negative breast cancer metastasis
por: Wiegmans, Adrian P, et al.
Publicado: (2014)

Translating the role of PARP inhibitors in triple-negative breast cancer
por: Beniey, Michèle, et al.
Publicado: (2019)

CRISPR/Cas9-induced saturated mutagenesis identifies Rad51 haplotype as a marker of PARP inhibitor sensitivity in breast cancer
por: Yang, Hua, et al.
Publicado: (2022)

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
por: Han, Ye, et al.
Publicado: (2020)

Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51
por: Lee, Jung Ok, et al.
Publicado: (2019)

PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction
por: Ray, Upasana, et al.
Publicado: (2023)

NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer
por: Zhou, Lei, et al.
Publicado: (2020)

Is There an Epigenetic Component Underlying the Resistance of Triple-Negative Breast Cancers to Parp Inhibitors?
por: Lovato, Amanda, et al.
Publicado: (2012)

Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer
por: Yordanova, Mariya, et al.
Publicado: (2021)

TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity
por: Moudry, Pavel, et al.
Publicado: (2016)

Checkpoint Kinase 1 (CHK1) Inhibition Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Proton Irradiation via Rad51 Downregulation
por: Choi, Changhoon, et al.
Publicado: (2020)

RAD51B in Familial Breast Cancer
por: Pelttari, Liisa M., et al.
Publicado: (2016)

RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy
por: Wiegmans, Adrian P., et al.
Publicado: (2016)

Dual PARP and RAD51 Inhibitory Drug Conjugates Show Synergistic and Selective Effects on Breast Cancer Cells
por: Malka, Matthews M., et al.
Publicado: (2021)

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
por: Cruz, C, et al.
Publicado: (2018)

KIAA1529 regulates RAD51 expression to confer PARP inhibitors resistance in ovarian cancer
por: Qiao, Yuan, et al.
Publicado: (2022)

Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer
por: Zhu, Ying, et al.
Publicado: (2023)

Depletion of DNA damage binding protein 2 sensitizes triple‐negative breast cancer cells to poly ADP‐ribose polymerase inhibition by destabilizing Rad51
por: Zhao, Lin, et al.
Publicado: (2019)

The cancer-testis gene, MEIOB, sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency
por: Gu, Yayun, et al.
Publicado: (2021)

Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D
por: Yang, Xin, et al.
Publicado: (2020)

Variation in the RAD51 gene and familial breast cancer
por: Lose, Felicity, et al.
Publicado: (2006)

SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers
por: Lu, Zhen, et al.
Publicado: (2022)

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells
por: Bajrami, Ilirjana, et al.
Publicado: (2012)

Effective targeting of breast cancer stem cells by combined inhibition of Sam68 and Rad51
por: Turdo, Alice, et al.
Publicado: (2022)

BLM and RAD51 Genes Polymorphism and Susceptibility to Breast Cancer
por: Sassi, Agnieszka, et al.
Publicado: (2013)

Polymorphisms in RAD51 and their relation with breast cancer in Saudi females
por: Tulbah, Sahar, et al.
Publicado: (2016)

Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
por: Zhu, Xiuzhi, et al.
Publicado: (2021)

p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors
por: Cañedo, Eduardo Cepeda, et al.
Publicado: (2021)

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
por: Barchiesi, Giacomo, et al.
Publicado: (2021)

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

Racial differences in RAD51 expression are regulated by miRNA-214-5P and its inhibition synergizes with olaparib in triple-negative breast cancer
por: Mani, Chinnadurai, et al.
Publicado: (2023)

Small molecule nitroalkenes inhibit RAD51-mediated homologous recombination and amplify triple-negative breast cancer cell killing by DNA-directed therapies
por: Hong, Lisa, et al.
Publicado: (2023)

Transcriptional profiles of different states of cancer stem cells in triple-negative breast cancer
por: Liu, Mingshan, et al.
Publicado: (2018)

BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib
por: Velazquez, Carolina, et al.
Publicado: (2023)

RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC
por: Xu, Jing, et al.
Publicado: (2023)

Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells
por: Moustafa, Dina, et al.
Publicado: (2021)

RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage
por: Haynes, Brittany M., et al.
Publicado: (2022)

Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study
por: Sankaranarayanan, Ramya Ambur, et al.
Publicado: (2022)

Mutation screening of RAD51C in male breast cancer patients
por: Silvestri, Valentina, et al.
Publicado: (2011)

RAD51C germline mutations in breast and ovarian cancer patients
por: Akbari, Mohammad R, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ev54uaknsikiki628dl577ah5j